{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T16:26:07Z","timestamp":1770567967918,"version":"3.49.0"},"reference-count":17,"publisher":"S. Karger AG","issue":"5-6","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2006]]},"abstract":"<i>Objective:<\/i> Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established. A phase I study was conducted to determine the maximum tolerated dose of S-1 with radiotherapy of 2 Gy\/day for 5 days a week to a total dose of 60 Gy. Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1. <i>Methods:<\/i> Concomitant administration with the above-mentioned radiotherapy of S-1 once a day for 2 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and 2 weeks on the drug with the dose escalating from S-1 60 mg\/body (level 1) to 80 mg\/body\/day (level 2), and then to 100 mg\/body\/day (level 3). <i>Results:<\/i> Twenty-one patients were valid for safety. Eighteen patients were enrolled in the dose-escalation phase. In all patients, S-1 was administered. The maximum tolerated dose was determined to be 100 mg\/body\/day and the dose-limiting toxicity was indicated by the onset of grade 3 chemoradiation dermatitis. Therefore, the determined recommended dose of S-1 was 80 mg\/body\/day. Objective response according to Response Evaluation Criteria in Solid Tumors were observed in 20 of 21 patients who had measurable disease (95.2%). <i>Conclusion:<\/i> Concurrent S-1 and radiotherapy was feasible and well tolerated, and was suggested to produce a worthwhile response in T2N0 glottic carcinoma. These results warrant further investigation, and a phase II has already been started.<\/jats:p>","DOI":"10.1159\/000108385","type":"journal-article","created":{"date-parts":[[2007,9,14]],"date-time":"2007-09-14T09:17:49Z","timestamp":1189761469000},"page":"369-373","source":"Crossref","is-referenced-by-count":24,"title":["A Phase I Study of Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Carcinoma"],"prefix":"10.1159","volume":"71","author":[{"given":"Hiroyuki","family":"Tsuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Kiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisaya","family":"Yukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Shimode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Tomoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2007,9,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097%2F00005537-200004000-00011"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819850501%2955%3A9%2B%3C2259%3A%3AAID-CNCR2820551432%3E3.0.CO%3B2-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.20181"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.oraloncology.2004.01.013"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F92.3.205"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.2820690526"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ijrobp.2005.06.014"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0360-3016%2898%2900321-6"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0167-8140%2897%2900048-0"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002%2Fhed.1081"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819850301%2955%3A5%3C1123%3A%3AAID-CNCR2820550530%3E3.0.CO%3B2-8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F86.4.265"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002%2F%28SICI%291097-0142%2819970201%2979%3A3%3C588%3A%3AAID-CNCR23%3E3.0.CO%3B2-Z"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016%2FS0889-8588%2805%2970086-1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2FS0360-3016%2800%2900663-5"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097%2F00001813-199810000-00012"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097%2F00001813-199607000-00010"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/108385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/108385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:58:28Z","timestamp":1745463508000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000108385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":17,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000108385","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}